Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KAT6A
REST API REST API
Homo sapiens
KAT6A is differentially expressed in 295 experiments: 124 organism parts: ovary, cerebellum, ... (122 more);, 222 disease states: normal, lung adenocarcinoma, ... (220 more);, 98 cell types 410 cell lines 44 compound treatments and 73 other conditions.
Synonyms MOZ, ZNF220, RUNXBP2, MYST3
Orthologs ENSCING00000008187 (Ciona intestinalis)   Myst3 (Rattus norvegicus)   Myst3 (Mus musculus)   KAT6A (Gallus gallus)   KAT6A (Bos taurus)   myst3 (Danio rerio)   ESA1 (Saccharomyces cerevisiae)   enok (Drosophila melanogaster)   KAT6A (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, histone acetyltransferase activity, regulation of transcription, DNA-dependent, acetyltransferase activity, transferase activity, transferring acyl groups other than amino-acyl groups, metal ion binding, transcription factor binding, transcription coactivator activity, nucleus, histone acetylation, nucleosome, histone H3 acetylation, chromatin modification, positive regulation of transcription, DNA-dependent, nucleosome assembly, zinc ion binding, MOZ/MORF histone acetyltransferase complex, myeloid cell differentiation, DNA packaging
InterPro Term Histone_H1/H5, Znf_PHD-finger, Znf_PHD, MOZ_SAS
UniProt Accession Q92794, A5PLL3, A5PKX7, C9K0F9
Search EB-eye ENSG00000083168
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
Jurkat
2
E-MEXP-2197, E-GEOD-1880
BT474
2
E-MTAB-62, E-MEXP-440
DU145
2
E-GEOD-17482, E-GEOD-20089
HepG2
2
E-MTAB-37, E-GEOD-7307
404 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21750, E-GEOD-2822, ... (50 experiments)

Factor Value U/D Experiments
2
2
E-TABM-145, E-TABM-130
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-TABM-145
macrophage
1
2
E-GEOD-22373, E-GEOD-3982, E-GEOD-8286
erythrocyte
1
E-MEXP-583
activated natural killer cell (supplemented for IL2 for 24 hours)
1
E-TABM-702
92 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (65 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
control
3
E-GEOD-21912, E-GEOD-16728, E-GEOD-16363
gastric carcinoma
3
E-GEOD-15460, E-MTAB-37, E-GEOD-2685
synovial sarcoma
2
E-MTAB-37, E-GEOD-6481
myeloma
2
E-MTAB-62, E-MTAB-37
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
216 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, E-TABM-782, ... (24 experiments)

Factor Value U/D Experiments
none
3
5
E-GEOD-412, E-TABM-782, E-GEOD-2803, E-GEOD-995, E-MEXP-1958, ... (8 experiments)
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
sapphyrin PCI-2051
1
E-GEOD-6400
nickel(II) chloride hexahydrate
1
E-GEOD-6907
phenol
1
E-GEOD-6907
estradiol
1
E-GEOD-20081
38 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
82
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2191, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-868, E-GEOD-18005, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-TABM-127, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (36 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-980, E-GEOD-17400

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 98 240
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Vehicle
studied in E-GEOD-5258

Processing time: 0.429 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM